Hogue SL, Bjoerk B, Walker A, Balp M, Fernandez MM, Quijano M, Ling CS, Heyes AE. Evidence-based market access value resource: navigating the hurdles for a biologic obtaining a license in a second indication in key European countries. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam. [abstract] Value Health. 2014 Nov; 17(7):A431-2.
Mahida S, Algarni M, Rittenhouse B. Effect of excluding non-patient benefits as an element on Acmg newborn screening (Nbs) recommendations. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 11, 2014. Amsterdam, Netherlands. [abstract] Value Health. 2014 Nov 1; 17(7):PA541. doi: 10.1016/j.jval.2014.08.1739
Novick D, Montgomery W, Aguado J, Duenas H, Haro JM. Symptomatic factors in patients with major depressive disorder (MDD): results from an observational study. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam, The Netherlands. [abstract] Value Health. 2014 Nov; 17(7):A543.
Novick D, Montgomery W, Treuer T, Aguado J, Kraemer S, Haro JM. Comparative effectiveness in terms of treatment discontinuation of orodispersable versus standard oral olanzapine tablets in non-adherent patients: results from a 1-year European outpatient observational study. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam, The Netherlands. [abstract] Value Health. 2014 Nov; 17(7):A766.
Novick D, Montgomery W, Treuer T, Aguado J, Kraemer S, Haro JM. Relationship of insight with medication adherence and the impact on outcomes in patients with schizophrenia and bipolar disorder: results from a 1-year European outpatient observational study. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam, The Netherlands. [abstract] Value Health. 2014 Nov; 17(7):A455.
Herring WL, Pearson IV, Purser MF, Nakhaipour HR, Haiderali A, Wolowacz SE, Jayasundara K. Cost-effectiveness of ofatumumab plus chlorambucil in first line chronic lymphocytic leukemia in Canada. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam, The Netherlands. [abstract] Value Health. 2014 Nov; 17(7):PA633.
Basarir H, Pollard D, Brennan A, Elliott J, Heller S, Campbell MJ. The potential value of ongoing support in type-1 diabetes mellitus with dafneplus: exploratory pre-trial cost-effectiveness analysis on proposed trial end-point target for 12-month Hba1c improvement. Presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam, The Netherlands. [abstract] Value Health. 2014 Nov; 17(7):A350. doi: 10.1016/j.jval.2014.08.725
Vass CM, Rigby D, Campbell S, Payne K. Investigating the framing-effects of risk attributes in discrete choice experiments: a pilot study. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam, The Netherlands. [abstract] Value Health. 2014 Nov; 17(7):A648. doi: 10.1016/j.jval.2014.08.2349
McLeod L. Review of the Task Force Report on PRO data collection in clinical trials using mixed modes. Value Health. 2014 Jul;17(5):491-2. doi: 10.1016/j.jval.2014.06.003
Strober B, Zhao Y, Tran MH, Gnanasakthy A, Nelson LM, McLeod LD, Mordin M, Gottlieb A, Elewski B, Lebwohl MG. Psychometric evaluation of the Psoriasis Symptom Diary using phase 3 trial data. Poster presented at the 2014 ISPOR 19th Annual International Meeting; May 2014. Montreal, Canada. [abstract] Value Health. 2014 Jun; 17(3):A288. doi: 10.1016/j.jval.2014.03.1676
Wilkins E, Fisher M, Brogan AJ, Talbird SE. Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naive adults with HIV-1 infection in the United Kingdom. Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 4, 2014. [abstract] Value Health. 2014 May; 17(3):A276.
Parikh R, Taychakhoonavudh S, White C, Franzini L. Sources of spending variation in professional services among Texas Hospital Referral Regions: an analysis of private insurance population. Poster presented at the 2011 ISPOR 16th Annual International Meeting; May 2014. Montreal, Canada. [abstract] Value Health. 2014 May; 17(3):A18. doi: 10.1016/j.jval.2014.03.116
Hauber AB, Nguyen H, Posner JD, Ervin CM, LaRue S, Kalsekar I. Patient preferences for frequency of glucagon-like peptide-1 receptor agonist (glp-1ra) injections in the treatment of type 2 diabetes. Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 4, 2014. [abstract] Value Health. 2014 May; 17(3):A255.
Schwab PE, Saundankar V, Bouchard J, Moretz C, Baltz J. Delayed treatment modifications for patients with type 2 diabetes mellitus with very poor glycemic control. Poster presented at the 2014 ISPOR 19th Annual International Meeting; May 31, 2014. Montreal, Canada. [abstract] Value Health. 2014 May; 17(3).
Ramamohan V, Mladsi DM, Kaye JA, Boey W, Pozzi R. An outcomes model for high-risk non-muscle-invasive bladder cancer treatment options. Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 2, 2014. Montreal, Canada. [abstract] Value Health. 2014 May; 17(3):A87.
Purser MF, Wilson MR, Mladsi DM, Wu Y. Literature review of economic models for the treatment of parkinson's disease. Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 2, 2014. Montreal, Canada. [abstract] Value Health. 2014 May; 17(3):A60. doi: 10.1016/j.jval.2014.03.355
Lewis S, Price M, Dwyer KA, O'Brien S, Heekin RD, Yates PJ, Beverland D, Mordin M. Development of a scale to assess performance following primary total knee arthroplasty. Value Health. 2014 Apr 21;17(4):350-9. doi: 10.1016/j.jval.2014.01.006
Karve SJ, Krishnarajah G, Korsnes JS, Cassidy A, Candrilli SD. Burden of acute gastroenteritis, norovirus and rotavirus in a managed care population. Hum Vaccin Immunother. 2014 Apr;10:1544-66. doi: 10.4161/hv.28704
Lairson DR, Parikh RC, Cormier JN, Du XL. Cost-utility analysis of platinum-based chemotherapy versus taxane and other regimens for ovarian cancer. Value Health. 2014 Feb;17(1):34-42.